Incidental Lewy body disease and preclinical Parkinson disease

Archives of Neurology

Volumn 65, Issue 8, 2008, Pages 1074-1080

  DelleDonne, Anthony ^a   Klos, Kevin J ^c   Fujishiro, Hiroshige ^a   Ahmed, Zeshan ^a,e   Parisi, Joseph E ^d   Josephs, Keith A ^d   Frigerio, Roberta ^d   Burnett, Melinda ^d   Wszolek, Zbigniew K ^b   Uitti, Ryan J ^b   Ahlskog, J Eric ^d   Dickson, Dennis W ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c Neurological Associates of Tulsa   (United States)

^d MAYO CLINIC   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CASE CONTROL STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; INCIDENTAL FINDING; MALE; MEDICAL RECORD; NERVE CELL DEGENERATION; ORGAN PRESERVATION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENTAL FINDINGS; LEWY BODY DISEASE; MALE; MIDDLE AGED; PARKINSON DISEASE; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 49449097043     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.8.1074     Document Type: Article

References (37)

1. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993 [published correction appears in Am J Epidemiol. 1996;143(5):528]. Am J Epidemiol. 1995;142(8):820-827.
2. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561-566.
3. Gibb WR. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol Appl Neurobiol. 1986;12(3):223-234.
4. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745-752.
5. Klos KJ, Ahlskog JE, Josephs KA, et al. α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology. 2006;66(7):1100-1102.
6. Ross GW, Petrovitch H, Abbott RD, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004;56(4):532-539.
7. Braak H, Bohl JR, Muller CM, et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006;21(12):2042-2051.
8. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
9. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5):2283-2301.
10. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
11. Reeves S, Bench C, Howard R. Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry. 2002;17(4):359-370.
12. Emborg ME, Ma SY, Mufson EJ, et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol. 1998;401(2):253-265.
13. Hedreen JC. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J Comp Neurol. 1999;409(3):400-410.
14. Irwin I, DeLanney LE, McNeill T, et al. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration. 1994;3(4):251-265.
15. Irwin I, Finnegan KT, Delanney LE, et al. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res. 1992;572(1-2):224-231.
16. Liang CL, Nelson O, Yazdani U, et al. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol. 2004;473(1):97-106.
17. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-39.
18. Verghese J, Buschke H, Kuslansky G, et al. Antemortem memory impairment screen performance is correlated with postmortem Alzheimer pathology. J Am Geriatr Soc. 2003;51(7):1043-1045.
19. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology. 2007;68(12):948-952.
20. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord. 2005;20(3):271-282.
21. Del Tredici K, Rub U, De Vos RA, et al. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61(5):413-426.
22. Beach TG, Adler CH, Sue LI, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008;115(4):445-451.
23. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128(pt 1):126-137.
24. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22(11):1581-1586.
25. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062- 2067.
26. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707.
27. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-1872.
28. 123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse. 2001;39(2):101-108.
29. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology. 1997;48(6):1578-1583.
30. Sherer TB, Kim JH, Betarbet R, et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp Neurol. 2003;179(1):9-16.
31. Klein RL, Dayton RD, Lin WL, et al. Tau gene transfer, but not α-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol Dis. 2005;20(1):64-73.
32. Fernandez-Espejo E. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol. 2004;29(1):15-30.
33. Unsicker K. Growth factors in Parkinson's disease. Prog Growth Factor Res. 1994;5(1):73-87.
34. Campbell DG, Hardie DG, Vulliet PR. Identification of four phosphorylation sites in the N-terminal region of tyrosine hydroxylase. J Biol Chem. 1986;261(23):10489-10492.
35. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem. 1996;67(2):443-462.
36. Ma SY, Collan Y, Roytta M, et al. Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol. 1995;21(1):10-17.
37. Hyman BT, Gomez-Isla T, Irizarry MC. Stereology: a practical primer for neuropathology. J Neuropathol Exp Neurol. 1998;57(4):305-310.